

# Global NAD+ Intravenous Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G580503405B7EN.html>

Date: February 2026

Pages: 108

Price: US\$ 3,480.00 (Single User License)

ID: G580503405B7EN

## Abstracts

According to our (Global Info Research) latest study, the global NAD+ Intravenous market size was valued at US\$ 102 million in 2025 and is forecast to a readjusted size of US\$ 174 million by 2032 with a CAGR of 8.1% during review period.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells and plays a crucial role in various biological processes, including energy metabolism and DNA repair. Intravenous (IV) administration of NAD+ involves delivering this coenzyme directly into the

### 1. Evidence-Driven Transition: NAD? IV Therapy Is Shifting from Concept-Based Anti-Aging to Clinically Validated Intervention

The most fundamental long-term trend for NAD? anti-aging intravenous therapy is its transition from a concept-driven wellness service toward an evidence-based clinical intervention. At present, most claimed benefits of NAD? IV?such as anti-fatigue, cognitive enhancement, metabolic optimization, and longevity?are primarily supported by mechanistic studies, animal models, or small observational trials, rather than large-scale randomized controlled trials (RCTs). As regulatory scrutiny increases and medical institutions demand higher scientific rigor, the industry will be forced to generate robust clinical evidence to validate therapeutic outcomes, define clear clinical indications, and demonstrate measurable improvements in objective biomarkers. Over time, NAD? IV is expected to evolve from a loosely defined ?anti-aging treatment? into a medically framed intervention with specific use cases, patient stratification, and standardized clinical endpoints.

### 2. Regulatory Tightening: NAD? IV Therapy Is Moving from a Gray Market into a

## Strongly Regulated Medical Framework

Another highly certain trend is the progressive tightening of regulatory oversight, which will push NAD<sup>+</sup> intravenous therapy out of its current semi-gray commercial zone and into a strictly regulated medical framework. In many markets today, NAD<sup>+</sup> IV is delivered through medical spas, wellness clinics, or functional medicine centers, often without clearly approved indications, standardized drug registration status, or consistent compliance with pharmaceutical regulations. As governments strengthen control over injectable therapies, compounded drugs, and medical advertising, NAD<sup>+</sup> IV services will increasingly be required to meet formal regulatory standards related to drug sourcing, sterile preparation, clinical justification, physician supervision, and liability management. This regulatory shift will significantly raise entry barriers and is expected to eliminate a large number of low-compliance providers, while favoring hospital systems, licensed clinics, and medically integrated institutions.

### 3. Safety and Quality Dominance: Sterility, Endotoxin Control, and Supply Chain Integrity Will Become Core Competitive Factors

Safety and pharmaceutical-grade quality control will become the central competitive axis of the NAD<sup>+</sup> IV industry as it matures. Intravenous administration inherently carries higher systemic risks than oral supplementation, placing stringent demands on sterile manufacturing, endotoxin control, formulation stability, dosage consistency, and cold-chain logistics. Currently, the market exhibits significant heterogeneity in raw material sourcing, preparation standards, and clinical protocols, creating potential safety vulnerabilities. In the future, sustainable operators will be those capable of implementing GMP-level production systems, batch traceability, sterility validation, adverse-event monitoring, and standardized infusion procedures. As a result, NAD<sup>+</sup> IV therapy will gradually resemble a pharmaceutical medical service rather than a consumer wellness product, with safety compliance itself becoming a major structural barrier to entry.

### 4. Product Pathway Differentiation: IV Administration Will Become a High-End Niche While Scalable Alternatives Expand

From a product strategy perspective, NAD<sup>+</sup> IV therapy is structurally constrained from becoming a mass-market solution due to its high operational costs, time-intensive administration, medical dependency, and variability in patient tolerance. As research and commercialization of NAD<sup>+</sup> precursors and alternative delivery methods continue to advance, market demand will increasingly shift toward more scalable, standardized, and consumer-friendly pathways. In this context, intravenous NAD<sup>+</sup> will gradually reposition

itself as a premium, specialized intervention within functional medicine, longevity clinics, and rehabilitation medicine, while larger market volumes will be captured by non-IV solutions. Long term, NAD<sup>+</sup> IV is more likely to remain a precision medical tool for specific high-value scenarios rather than a mainstream anti-aging modality.

## 5. Business Model Evolution: From One-Time Anti-Aging Services to Longitudinal Medical Management Systems

The commercial model of NAD<sup>+</sup> IV therapy is expected to evolve from transaction-based ?anti-aging packages? toward longitudinal medical management systems centered on patient stratification and data feedback. As consumers become more scientifically informed and regulators restrict exaggerated longevity claims, simple service-selling models will lose sustainability. Instead, leading providers will integrate NAD<sup>+</sup> IV into broader functional medicine frameworks, supported by baseline diagnostics, biomarker tracking, patient segmentation, and outcome monitoring. In this emerging model, NAD<sup>+</sup> IV is no longer positioned as a standalone product, but as one component within a personalized health optimization ecosystem, where long-term value is generated through continuous medical engagement, data accumulation, and outcome-based service delivery.

This report is a detailed and comprehensive analysis for global NAD<sup>+</sup> Intravenous market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

### **Key Features:**

Global NAD<sup>+</sup> Intravenous market size and forecasts, in consumption value (\$ Million), 2021-2032

Global NAD<sup>+</sup> Intravenous market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global NAD<sup>+</sup> Intravenous market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global NAD+ Intravenous market shares of main players, in revenue (\$ Million),  
2021-2026

### **The Primary Objectives in This Report Are:**

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for NAD+ Intravenous

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global NAD+ Intravenous market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include The Wellness Lab, Conciergemdl, Azivmedics, Reset IV, Thedripclub, Toronto Functional Medicine Centre, Mobileivmedics, Rocky Mountain Ivmedics, Premiumhealth, Effect Doctors, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

### **Market segmentation**

NAD+ Intravenous market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Hybrid Type

Pure NAD+ Type

## Market segment by Injection

Single-use Injection Type

Recurring Injection Type

Others

## Market segment by Dose

Low-dose Type

Medium-dose Type

High-dose Type

## Market segment by Application

Clinic

Hospital

Other

## Market segment by players, this report covers

The Wellness Lab

Conciergemdla

Azivmedics

Reset IV

The dripclub

Toronto Functional Medicine Centre

Mobileivmedics

Rocky Mountain Ivmedics

Premiumhealth

Effect Doctors

Nadclinic

Hydrate IV Bar

LIVV Natural

BioReset Medical

IV Boost UK

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

**The content of the study subjects, includes a total of 13 chapters:**

Chapter 1, to describe NAD+ Intravenous product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of NAD+ Intravenous, with revenue, gross margin, and global market share of NAD+ Intravenous from 2021 to 2026.

Chapter 3, the NAD+ Intravenous competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and NAD+ Intravenous market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of NAD+ Intravenous.

Chapter 13, to describe NAD+ Intravenous research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of NAD+ Intravenous by Type

1.3.1 Overview: Global NAD+ Intravenous Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global NAD+ Intravenous Consumption Value Market Share by Type in 2025

1.3.3 Hybrid Type

1.3.4 Pure NAD+ Type

1.4 Classification of NAD+ Intravenous by Injection

1.4.1 Overview: Global NAD+ Intravenous Market Size by Injection: 2021 Versus 2025 Versus 2032

1.4.2 Global NAD+ Intravenous Consumption Value Market Share by Injection in 2025

1.4.3 Single-use Injection Type

1.4.4 Recurring Injection Type

1.4.5 Others

1.5 Classification of NAD+ Intravenous by Dose

1.5.1 Overview: Global NAD+ Intravenous Market Size by Dose: 2021 Versus 2025 Versus 2032

1.5.2 Global NAD+ Intravenous Consumption Value Market Share by Dose in 2025

1.5.3 Low-dose Type

1.5.4 Medium-dose Type

1.5.5 High-dose Type

1.6 Global NAD+ Intravenous Market by Application

1.6.1 Overview: Global NAD+ Intravenous Market Size by Application: 2021 Versus 2025 Versus 2032

1.6.2 Clinic

1.6.3 Hospital

1.6.4 Other

1.7 Global NAD+ Intravenous Market Size & Forecast

1.8 Global NAD+ Intravenous Market Size and Forecast by Region

1.8.1 Global NAD+ Intravenous Market Size by Region: 2021 VS 2025 VS 2032

1.8.2 Global NAD+ Intravenous Market Size by Region, (2021-2032)

1.8.3 North America NAD+ Intravenous Market Size and Prospect (2021-2032)

1.8.4 Europe NAD+ Intravenous Market Size and Prospect (2021-2032)

1.8.5 Asia-Pacific NAD+ Intravenous Market Size and Prospect (2021-2032)

- 1.8.6 South America NAD+ Intravenous Market Size and Prospect (2021-2032)
- 1.8.7 Middle East & Africa NAD+ Intravenous Market Size and Prospect (2021-2032)

## **2 COMPANY PROFILES**

### 2.1 The Wellness Lab

- 2.1.1 The Wellness Lab Details
- 2.1.2 The Wellness Lab Major Business
- 2.1.3 The Wellness Lab NAD+ Intravenous Product and Solutions
- 2.1.4 The Wellness Lab NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 The Wellness Lab Recent Developments and Future Plans

### 2.2 Conciergemdlá

- 2.2.1 Conciergemdlá Details
- 2.2.2 Conciergemdlá Major Business
- 2.2.3 Conciergemdlá NAD+ Intravenous Product and Solutions
- 2.2.4 Conciergemdlá NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Conciergemdlá Recent Developments and Future Plans

### 2.3 Azivmedics

- 2.3.1 Azivmedics Details
- 2.3.2 Azivmedics Major Business
- 2.3.3 Azivmedics NAD+ Intravenous Product and Solutions
- 2.3.4 Azivmedics NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Azivmedics Recent Developments and Future Plans

### 2.4 Reset IV

- 2.4.1 Reset IV Details
- 2.4.2 Reset IV Major Business
- 2.4.3 Reset IV NAD+ Intravenous Product and Solutions
- 2.4.4 Reset IV NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Reset IV Recent Developments and Future Plans

### 2.5 Thedripclub

- 2.5.1 Thedripclub Details
- 2.5.2 Thedripclub Major Business
- 2.5.3 Thedripclub NAD+ Intravenous Product and Solutions
- 2.5.4 Thedripclub NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)

- 2.5.5 Thedripclub Recent Developments and Future Plans
- 2.6 Toronto Functional Medicine Centre
  - 2.6.1 Toronto Functional Medicine Centre Details
  - 2.6.2 Toronto Functional Medicine Centre Major Business
  - 2.6.3 Toronto Functional Medicine Centre NAD+ Intravenous Product and Solutions
  - 2.6.4 Toronto Functional Medicine Centre NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.6.5 Toronto Functional Medicine Centre Recent Developments and Future Plans
- 2.7 Mobileivmedics
  - 2.7.1 Mobileivmedics Details
  - 2.7.2 Mobileivmedics Major Business
  - 2.7.3 Mobileivmedics NAD+ Intravenous Product and Solutions
  - 2.7.4 Mobileivmedics NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.7.5 Mobileivmedics Recent Developments and Future Plans
- 2.8 Rocky Mountain Ivmedics
  - 2.8.1 Rocky Mountain Ivmedics Details
  - 2.8.2 Rocky Mountain Ivmedics Major Business
  - 2.8.3 Rocky Mountain Ivmedics NAD+ Intravenous Product and Solutions
  - 2.8.4 Rocky Mountain Ivmedics NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.8.5 Rocky Mountain Ivmedics Recent Developments and Future Plans
- 2.9 Premiumhealth
  - 2.9.1 Premiumhealth Details
  - 2.9.2 Premiumhealth Major Business
  - 2.9.3 Premiumhealth NAD+ Intravenous Product and Solutions
  - 2.9.4 Premiumhealth NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.9.5 Premiumhealth Recent Developments and Future Plans
- 2.10 Effect Doctors
  - 2.10.1 Effect Doctors Details
  - 2.10.2 Effect Doctors Major Business
  - 2.10.3 Effect Doctors NAD+ Intravenous Product and Solutions
  - 2.10.4 Effect Doctors NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.10.5 Effect Doctors Recent Developments and Future Plans
- 2.11 Nadclinic
  - 2.11.1 Nadclinic Details
  - 2.11.2 Nadclinic Major Business

- 2.11.3 Nadclinic NAD+ Intravenous Product and Solutions
- 2.11.4 Nadclinic NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Nadclinic Recent Developments and Future Plans
- 2.12 Hydrate IV Bar
  - 2.12.1 Hydrate IV Bar Details
  - 2.12.2 Hydrate IV Bar Major Business
  - 2.12.3 Hydrate IV Bar NAD+ Intravenous Product and Solutions
  - 2.12.4 Hydrate IV Bar NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.12.5 Hydrate IV Bar Recent Developments and Future Plans
- 2.13 LIVV Natural
  - 2.13.1 LIVV Natural Details
  - 2.13.2 LIVV Natural Major Business
  - 2.13.3 LIVV Natural NAD+ Intravenous Product and Solutions
  - 2.13.4 LIVV Natural NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.13.5 LIVV Natural Recent Developments and Future Plans
- 2.14 BioReset Medical
  - 2.14.1 BioReset Medical Details
  - 2.14.2 BioReset Medical Major Business
  - 2.14.3 BioReset Medical NAD+ Intravenous Product and Solutions
  - 2.14.4 BioReset Medical NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.14.5 BioReset Medical Recent Developments and Future Plans
- 2.15 IV Boost UK
  - 2.15.1 IV Boost UK Details
  - 2.15.2 IV Boost UK Major Business
  - 2.15.3 IV Boost UK NAD+ Intravenous Product and Solutions
  - 2.15.4 IV Boost UK NAD+ Intravenous Revenue, Gross Margin and Market Share (2021-2026)
  - 2.15.5 IV Boost UK Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

- 3.1 Global NAD+ Intravenous Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
  - 3.2.1 Market Share of NAD+ Intravenous by Company Revenue
  - 3.2.2 Top 3 NAD+ Intravenous Players Market Share in 2025

- 3.2.3 Top 6 NAD+ Intravenous Players Market Share in 2025
- 3.3 NAD+ Intravenous Market: Overall Company Footprint Analysis
  - 3.3.1 NAD+ Intravenous Market: Region Footprint
  - 3.3.2 NAD+ Intravenous Market: Company Product Type Footprint
  - 3.3.3 NAD+ Intravenous Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

- 4.1 Global NAD+ Intravenous Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global NAD+ Intravenous Market Forecast by Type (2027-2032)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

- 5.1 Global NAD+ Intravenous Consumption Value Market Share by Application (2021-2026)
- 5.2 Global NAD+ Intravenous Market Forecast by Application (2027-2032)

## **6 NORTH AMERICA**

- 6.1 North America NAD+ Intravenous Consumption Value by Type (2021-2032)
- 6.2 North America NAD+ Intravenous Market Size by Application (2021-2032)
- 6.3 North America NAD+ Intravenous Market Size by Country
  - 6.3.1 North America NAD+ Intravenous Consumption Value by Country (2021-2032)
  - 6.3.2 United States NAD+ Intravenous Market Size and Forecast (2021-2032)
  - 6.3.3 Canada NAD+ Intravenous Market Size and Forecast (2021-2032)
  - 6.3.4 Mexico NAD+ Intravenous Market Size and Forecast (2021-2032)

## **7 EUROPE**

- 7.1 Europe NAD+ Intravenous Consumption Value by Type (2021-2032)
- 7.2 Europe NAD+ Intravenous Consumption Value by Application (2021-2032)
- 7.3 Europe NAD+ Intravenous Market Size by Country
  - 7.3.1 Europe NAD+ Intravenous Consumption Value by Country (2021-2032)
  - 7.3.2 Germany NAD+ Intravenous Market Size and Forecast (2021-2032)
  - 7.3.3 France NAD+ Intravenous Market Size and Forecast (2021-2032)
  - 7.3.4 United Kingdom NAD+ Intravenous Market Size and Forecast (2021-2032)

7.3.5 Russia NAD+ Intravenous Market Size and Forecast (2021-2032)

7.3.6 Italy NAD+ Intravenous Market Size and Forecast (2021-2032)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific NAD+ Intravenous Consumption Value by Type (2021-2032)

8.2 Asia-Pacific NAD+ Intravenous Consumption Value by Application (2021-2032)

8.3 Asia-Pacific NAD+ Intravenous Market Size by Region

8.3.1 Asia-Pacific NAD+ Intravenous Consumption Value by Region (2021-2032)

8.3.2 China NAD+ Intravenous Market Size and Forecast (2021-2032)

8.3.3 Japan NAD+ Intravenous Market Size and Forecast (2021-2032)

8.3.4 South Korea NAD+ Intravenous Market Size and Forecast (2021-2032)

8.3.5 India NAD+ Intravenous Market Size and Forecast (2021-2032)

8.3.6 Southeast Asia NAD+ Intravenous Market Size and Forecast (2021-2032)

8.3.7 Australia NAD+ Intravenous Market Size and Forecast (2021-2032)

## **9 SOUTH AMERICA**

9.1 South America NAD+ Intravenous Consumption Value by Type (2021-2032)

9.2 South America NAD+ Intravenous Consumption Value by Application (2021-2032)

9.3 South America NAD+ Intravenous Market Size by Country

9.3.1 South America NAD+ Intravenous Consumption Value by Country (2021-2032)

9.3.2 Brazil NAD+ Intravenous Market Size and Forecast (2021-2032)

9.3.3 Argentina NAD+ Intravenous Market Size and Forecast (2021-2032)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa NAD+ Intravenous Consumption Value by Type (2021-2032)

10.2 Middle East & Africa NAD+ Intravenous Consumption Value by Application (2021-2032)

10.3 Middle East & Africa NAD+ Intravenous Market Size by Country

10.3.1 Middle East & Africa NAD+ Intravenous Consumption Value by Country (2021-2032)

10.3.2 Turkey NAD+ Intravenous Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia NAD+ Intravenous Market Size and Forecast (2021-2032)

10.3.4 UAE NAD+ Intravenous Market Size and Forecast (2021-2032)

## **11 MARKET DYNAMICS**

- 11.1 NAD+ Intravenous Market Drivers
- 11.2 NAD+ Intravenous Market Restraints
- 11.3 NAD+ Intravenous Trends Analysis
- 11.4 Porters Five Forces Analysis
  - 11.4.1 Threat of New Entrants
  - 11.4.2 Bargaining Power of Suppliers
  - 11.4.3 Bargaining Power of Buyers
  - 11.4.4 Threat of Substitutes
  - 11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

- 12.1 NAD+ Intravenous Industry Chain
- 12.2 NAD+ Intravenous Upstream Analysis
- 12.3 NAD+ Intravenous Midstream Analysis
- 12.4 NAD+ Intravenous Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Global NAD+ Intravenous Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Table 2. Global NAD+ Intravenous Consumption Value by Injection, (USD Million), 2021 & 2025 & 2032
- Table 3. Global NAD+ Intravenous Consumption Value by Dose, (USD Million), 2021 & 2025 & 2032
- Table 4. Global NAD+ Intravenous Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Table 5. Global NAD+ Intravenous Consumption Value by Region (2021-2026) & (USD Million)
- Table 6. Global NAD+ Intravenous Consumption Value by Region (2027-2032) & (USD Million)
- Table 7. The Wellness Lab Company Information, Head Office, and Major Competitors
- Table 8. The Wellness Lab Major Business
- Table 9. The Wellness Lab NAD+ Intravenous Product and Solutions
- Table 10. The Wellness Lab NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 11. The Wellness Lab Recent Developments and Future Plans
- Table 12. Conciergemda Company Information, Head Office, and Major Competitors
- Table 13. Conciergemda Major Business
- Table 14. Conciergemda NAD+ Intravenous Product and Solutions
- Table 15. Conciergemda NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 16. Conciergemda Recent Developments and Future Plans
- Table 17. Azivmedics Company Information, Head Office, and Major Competitors
- Table 18. Azivmedics Major Business
- Table 19. Azivmedics NAD+ Intravenous Product and Solutions
- Table 20. Azivmedics NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 21. Reset IV Company Information, Head Office, and Major Competitors
- Table 22. Reset IV Major Business
- Table 23. Reset IV NAD+ Intravenous Product and Solutions
- Table 24. Reset IV NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 25. Reset IV Recent Developments and Future Plans

Table 26. Thedripclub Company Information, Head Office, and Major Competitors

Table 27. Thedripclub Major Business

Table 28. Thedripclub NAD+ Intravenous Product and Solutions

Table 29. Thedripclub NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 30. Thedripclub Recent Developments and Future Plans

Table 31. Toronto Functional Medicine Centre Company Information, Head Office, and Major Competitors

Table 32. Toronto Functional Medicine Centre Major Business

Table 33. Toronto Functional Medicine Centre NAD+ Intravenous Product and Solutions

Table 34. Toronto Functional Medicine Centre NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 35. Toronto Functional Medicine Centre Recent Developments and Future Plans

Table 36. Mobileivmedics Company Information, Head Office, and Major Competitors

Table 37. Mobileivmedics Major Business

Table 38. Mobileivmedics NAD+ Intravenous Product and Solutions

Table 39. Mobileivmedics NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 40. Mobileivmedics Recent Developments and Future Plans

Table 41. Rocky Mountain Ivmedics Company Information, Head Office, and Major Competitors

Table 42. Rocky Mountain Ivmedics Major Business

Table 43. Rocky Mountain Ivmedics NAD+ Intravenous Product and Solutions

Table 44. Rocky Mountain Ivmedics NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 45. Rocky Mountain Ivmedics Recent Developments and Future Plans

Table 46. Premiumhealth Company Information, Head Office, and Major Competitors

Table 47. Premiumhealth Major Business

Table 48. Premiumhealth NAD+ Intravenous Product and Solutions

Table 49. Premiumhealth NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 50. Premiumhealth Recent Developments and Future Plans

Table 51. Effect Doctors Company Information, Head Office, and Major Competitors

Table 52. Effect Doctors Major Business

Table 53. Effect Doctors NAD+ Intravenous Product and Solutions

Table 54. Effect Doctors NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 55. Effect Doctors Recent Developments and Future Plans

Table 56. Nadclinic Company Information, Head Office, and Major Competitors

- Table 57. Nadclinic Major Business
- Table 58. Nadclinic NAD+ Intravenous Product and Solutions
- Table 59. Nadclinic NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 60. Nadclinic Recent Developments and Future Plans
- Table 61. Hydrate IV Bar Company Information, Head Office, and Major Competitors
- Table 62. Hydrate IV Bar Major Business
- Table 63. Hydrate IV Bar NAD+ Intravenous Product and Solutions
- Table 64. Hydrate IV Bar NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 65. Hydrate IV Bar Recent Developments and Future Plans
- Table 66. LIVV Natural Company Information, Head Office, and Major Competitors
- Table 67. LIVV Natural Major Business
- Table 68. LIVV Natural NAD+ Intravenous Product and Solutions
- Table 69. LIVV Natural NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 70. LIVV Natural Recent Developments and Future Plans
- Table 71. BioReset Medical Company Information, Head Office, and Major Competitors
- Table 72. BioReset Medical Major Business
- Table 73. BioReset Medical NAD+ Intravenous Product and Solutions
- Table 74. BioReset Medical NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 75. BioReset Medical Recent Developments and Future Plans
- Table 76. IV Boost UK Company Information, Head Office, and Major Competitors
- Table 77. IV Boost UK Major Business
- Table 78. IV Boost UK NAD+ Intravenous Product and Solutions
- Table 79. IV Boost UK NAD+ Intravenous Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 80. IV Boost UK Recent Developments and Future Plans
- Table 81. Global NAD+ Intravenous Revenue (USD Million) by Players (2021-2026)
- Table 82. Global NAD+ Intravenous Revenue Share by Players (2021-2026)
- Table 83. Breakdown of NAD+ Intravenous by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 84. Market Position of Players in NAD+ Intravenous, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
- Table 85. Head Office of Key NAD+ Intravenous Players
- Table 86. NAD+ Intravenous Market: Company Product Type Footprint
- Table 87. NAD+ Intravenous Market: Company Product Application Footprint
- Table 88. NAD+ Intravenous New Market Entrants and Barriers to Market Entry

Table 89. NAD+ Intravenous Mergers, Acquisition, Agreements, and Collaborations

Table 90. Global NAD+ Intravenous Consumption Value (USD Million) by Type (2021-2026)

Table 91. Global NAD+ Intravenous Consumption Value Share by Type (2021-2026)

Table 92. Global NAD+ Intravenous Consumption Value Forecast by Type (2027-2032)

Table 93. Global NAD+ Intravenous Consumption Value by Application (2021-2026)

Table 94. Global NAD+ Intravenous Consumption Value Forecast by Application (2027-2032)

Table 95. North America NAD+ Intravenous Consumption Value by Type (2021-2026) & (USD Million)

Table 96. North America NAD+ Intravenous Consumption Value by Type (2027-2032) & (USD Million)

Table 97. North America NAD+ Intravenous Consumption Value by Application (2021-2026) & (USD Million)

Table 98. North America NAD+ Intravenous Consumption Value by Application (2027-2032) & (USD Million)

Table 99. North America NAD+ Intravenous Consumption Value by Country (2021-2026) & (USD Million)

Table 100. North America NAD+ Intravenous Consumption Value by Country (2027-2032) & (USD Million)

Table 101. Europe NAD+ Intravenous Consumption Value by Type (2021-2026) & (USD Million)

Table 102. Europe NAD+ Intravenous Consumption Value by Type (2027-2032) & (USD Million)

Table 103. Europe NAD+ Intravenous Consumption Value by Application (2021-2026) & (USD Million)

Table 104. Europe NAD+ Intravenous Consumption Value by Application (2027-2032) & (USD Million)

Table 105. Europe NAD+ Intravenous Consumption Value by Country (2021-2026) & (USD Million)

Table 106. Europe NAD+ Intravenous Consumption Value by Country (2027-2032) & (USD Million)

Table 107. Asia-Pacific NAD+ Intravenous Consumption Value by Type (2021-2026) & (USD Million)

Table 108. Asia-Pacific NAD+ Intravenous Consumption Value by Type (2027-2032) & (USD Million)

Table 109. Asia-Pacific NAD+ Intravenous Consumption Value by Application (2021-2026) & (USD Million)

Table 110. Asia-Pacific NAD+ Intravenous Consumption Value by Application

(2027-2032) & (USD Million)

Table 111. Asia-Pacific NAD+ Intravenous Consumption Value by Region (2021-2026) & (USD Million)

Table 112. Asia-Pacific NAD+ Intravenous Consumption Value by Region (2027-2032) & (USD Million)

Table 113. South America NAD+ Intravenous Consumption Value by Type (2021-2026) & (USD Million)

Table 114. South America NAD+ Intravenous Consumption Value by Type (2027-2032) & (USD Million)

Table 115. South America NAD+ Intravenous Consumption Value by Application (2021-2026) & (USD Million)

Table 116. South America NAD+ Intravenous Consumption Value by Application (2027-2032) & (USD Million)

Table 117. South America NAD+ Intravenous Consumption Value by Country (2021-2026) & (USD Million)

Table 118. South America NAD+ Intravenous Consumption Value by Country (2027-2032) & (USD Million)

Table 119. Middle East & Africa NAD+ Intravenous Consumption Value by Type (2021-2026) & (USD Million)

Table 120. Middle East & Africa NAD+ Intravenous Consumption Value by Type (2027-2032) & (USD Million)

Table 121. Middle East & Africa NAD+ Intravenous Consumption Value by Application (2021-2026) & (USD Million)

Table 122. Middle East & Africa NAD+ Intravenous Consumption Value by Application (2027-2032) & (USD Million)

Table 123. Middle East & Africa NAD+ Intravenous Consumption Value by Country (2021-2026) & (USD Million)

Table 124. Middle East & Africa NAD+ Intravenous Consumption Value by Country (2027-2032) & (USD Million)

Table 125. Global Key Players of NAD+ Intravenous Upstream (Raw Materials)

Table 126. Global NAD+ Intravenous Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. NAD+ Intravenous Picture

Figure 2. Global NAD+ Intravenous Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global NAD+ Intravenous Consumption Value Market Share by Type in 2025

Figure 4. Hybrid Type

Figure 5. Pure NAD+ Type

Figure 6. Global NAD+ Intravenous Consumption Value by Injection, (USD Million), 2021 & 2025 & 2032

Figure 7. Global NAD+ Intravenous Consumption Value Market Share by Injection in 2025

Figure 8. Single-use Injection Type

Figure 9. Recurring Injection Type

Figure 10. Others

Figure 11. Global NAD+ Intravenous Consumption Value by Dose, (USD Million), 2021 & 2025 & 2032

Figure 12. Global NAD+ Intravenous Consumption Value Market Share by Dose in 2025

Figure 13. Low-dose Type

Figure 14. Medium-dose Type

Figure 15. High-dose Type

Figure 16. Global NAD+ Intravenous Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 17. NAD+ Intravenous Consumption Value Market Share by Application in 2025

Figure 18. Clinic Picture

Figure 19. Hospital Picture

Figure 20. Other Picture

Figure 21. Global NAD+ Intravenous Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 22. Global NAD+ Intravenous Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 23. Global Market NAD+ Intravenous Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)

Figure 24. Global NAD+ Intravenous Consumption Value Market Share by Region (2021-2032)

Figure 25. Global NAD+ Intravenous Consumption Value Market Share by Region in 2025

Figure 26. North America NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 27. Europe NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 28. Asia-Pacific NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 29. South America NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 30. Middle East & Africa NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 31. Company Three Recent Developments and Future Plans

Figure 32. Global NAD+ Intravenous Revenue Share by Players in 2025

Figure 33. NAD+ Intravenous Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 34. Market Share of NAD+ Intravenous by Player Revenue in 2025

Figure 35. Top 3 NAD+ Intravenous Players Market Share in 2025

Figure 36. Top 6 NAD+ Intravenous Players Market Share in 2025

Figure 37. Global NAD+ Intravenous Consumption Value Share by Type (2021-2026)

Figure 38. Global NAD+ Intravenous Market Share Forecast by Type (2027-2032)

Figure 39. Global NAD+ Intravenous Consumption Value Share by Application (2021-2026)

Figure 40. Global NAD+ Intravenous Market Share Forecast by Application (2027-2032)

Figure 41. North America NAD+ Intravenous Consumption Value Market Share by Type (2021-2032)

Figure 42. North America NAD+ Intravenous Consumption Value Market Share by Application (2021-2032)

Figure 43. North America NAD+ Intravenous Consumption Value Market Share by Country (2021-2032)

Figure 44. United States NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 45. Canada NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 46. Mexico NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

Figure 47. Europe NAD+ Intravenous Consumption Value Market Share by Type (2021-2032)

Figure 48. Europe NAD+ Intravenous Consumption Value Market Share by Application (2021-2032)

Figure 49. Europe NAD+ Intravenous Consumption Value Market Share by Country (2021-2032)

Figure 50. Germany NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

- Figure 51. France NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 52. United Kingdom NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 53. Russia NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 54. Italy NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 55. Asia-Pacific NAD+ Intravenous Consumption Value Market Share by Type (2021-2032)
- Figure 56. Asia-Pacific NAD+ Intravenous Consumption Value Market Share by Application (2021-2032)
- Figure 57. Asia-Pacific NAD+ Intravenous Consumption Value Market Share by Region (2021-2032)
- Figure 58. China NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 59. Japan NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 60. South Korea NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 61. India NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 62. Southeast Asia NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 63. Australia NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 64. South America NAD+ Intravenous Consumption Value Market Share by Type (2021-2032)
- Figure 65. South America NAD+ Intravenous Consumption Value Market Share by Application (2021-2032)
- Figure 66. South America NAD+ Intravenous Consumption Value Market Share by Country (2021-2032)
- Figure 67. Brazil NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 68. Argentina NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 69. Middle East & Africa NAD+ Intravenous Consumption Value Market Share by Type (2021-2032)
- Figure 70. Middle East & Africa NAD+ Intravenous Consumption Value Market Share by Application (2021-2032)
- Figure 71. Middle East & Africa NAD+ Intravenous Consumption Value Market Share by Country (2021-2032)
- Figure 72. Turkey NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 73. Saudi Arabia NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)
- Figure 74. UAE NAD+ Intravenous Consumption Value (2021-2032) & (USD Million)

- Figure 75. NAD+ Intravenous Market Drivers
- Figure 76. NAD+ Intravenous Market Restraints
- Figure 77. NAD+ Intravenous Market Trends
- Figure 78. Porters Five Forces Analysis
- Figure 79. NAD+ Intravenous Industrial Chain
- Figure 80. Methodology
- Figure 81. Research Process and Data Source

## I would like to order

Product name: Global NAD+ Intravenous Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G580503405B7EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G580503405B7EN.html>